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Nanoparticle contrast agents are useful tools to label stem cells and monitor the in vivo bio-distribution of
labeled cells in pre-clinical models of disease. In this context, understanding the in vivo fate of the particles
after injection of labelled cells is important for their eventual clinical use as well as for the interpretation of
imaging results. We examined how the formulation of superparamagnetic iron oxide nanoparticles (SPIONs)
impacts the labelling eﬃciency, magnetic characteristics and fate of the particles by comparing individual
SPIONs with polyelectrolyte multilayer capsules containing SPIONs. At low labelling concentration,
encapsulated SPIONs served as an eﬃcient labelling agent for stem cells. The bio-distribution after intra-
cardiac injection of labelled cells was monitored longitudinally by MRI and as an endpoint by inductively
coupled plasma-optical emission spectrometry. The results suggest that, after being released from
labelled cells after cell death, both formulations of particles are initially stored in liver and spleen and are
not completely cleared from these organs 2 weeks post-injection.Introduction
Stem cell regenerative medicine therapies have been
proposed for the treatment of a range of debilitating condi-
tions.1–4 Tracking of stem cells in pre-clinical models is
a prerequisite to determine their safety and eﬃcacy.5–7 For
this purpose, in addition to, and/or in combination with
genetic reporters, nanoparticles are successfully used as
contrast agents for cell labelling and tracking with various
imaging modalities.8–12
Cellular biodistribution, viability and proliferation can be
monitored by bioluminescence imaging (BLI) of the cells
transduced with the genetic reporter rey luciferase (Luc).12–14
Cell death results in a decrease in bioluminescence signal,
whilst cell division and tumor formation leads to an ampli-
cation of the signal. This is a highly sensitive and robust
method of monitoring the biodistribution of cells though it has
a low spatial resolution (intra and inter organ monitoring of
cells distribution is not possible).15Integrative Biology (IIB), University of
erpool.ac.uk; sumaira@liverpool.ac.uk
iology, Institute of Translational Medicine
ranslational Medicine (ITM), University of
erpool, Liverpool, UK
, Glasgow, UK
tion (ESI) available. See DOI:
Chemistry 2018Magnetic resonance imaging (MRI) oﬀers much higher
spatial resolution (50 mm) than BLI allowing in vivo cell tracking
combined with detailed anatomical information at the level of
individual organs.16 Appropriate MRI contrast agents17,18 for cell
tracking include superparamagnetic iron oxide nanoparticles
(SPIONs) which generate a negative contrast.11,19–24 The uptake
eﬃciency of SPIONs by cells is strongly inuenced by the
functionalization of SPIONs.21,25 Recently, positively-charged
DEAE (diethylaminoethyl)-dextran coated SPIONs have been
synthesized for enhanced cellular uptake and MRI contrast.20,22
Upon cell uptake, the clustering and connement of these
particles in endosomal and lysosomal compartments aﬀects
their abilities to alter the relaxation rate and hence relaxivity of
the surrounding water molecules.26,27 The critical parameter for
imaging is the contrast obtained aer cell labelling rather than
the solution relaxivity of the particles.20,22
One potential approach to enhance SPIONs uptake by cells,
is to assemble them inside polymeric capsules resulting in the
packing of large amount of individual nanoparticles within
a conned volume.28–30 Polyelectrolyte multilayered (PEM) and
multifunctional capsules are fabricated by layer-by-layer (LbL)
assembly of oppositely charged polymeric layers around
a template.31 Their design can be tailored using multiple strat-
egies and particle loading can be enhanced by including addi-
tional layers of particles during the capsule's assembly.32 The
choice of the nal polymer layer determines their cellular
interaction, uptake eﬃciency and hence internalization. It has
been observed that a nal layer of positively charged polymers
results in increased uptake of capsules.33 For long term cellularNanoscale Advances
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View Article Onlineimaging the walls of the capsules can be made of non-
biodegradable materials.34
We and others have shown that most imaging contrast
labelled cells used for regenerative medicine therapies
including stem cells, die aer injection.11,15,35 Therefore,
understanding the in vivo fate of cell-labelling nanoparticles,
especially following the death of the labelled cells is important
for the interpretation of imaging studies and to assess the risk
of toxicity. In the current study, we focus on the eﬀect of
formulation on the fate of SPIONs aer the in vivo injection of
labelled cells. More specically, we labelled mouse bone
marrow derivedmesenchymal stem cells (mMSCs) with free and
PEM-encapsulated SPIONs. First the solution relaxivities,
magnetic properties, toxicity, and cell labelling eﬃciency of
both formulations of particles are compared. Then, aer intra-
cardially (IC) injecting the labelled cells in the le ventricle of
mice, the animals were longitudinally imaged by BLI and MRI
until 14 days post injection. The cellular bio-distribution and
viability was monitored by BLI, whilst MRI allowed visualization
of the in vivo fate of particles aer cell death. At the end point of
experiments (2 weeks post-injection), the amount of elemental
iron inside the organs was measured to analyze the accumula-
tion and elimination of both formulations of SPIONs. Our
studies demonstrate a similar accumulation and elimination
pattern of particles injected via labelled cells to what has been
reported for the particles directly injected in the blood
stream.36–40Results and discussion
Preparation and characterization of free and encapsulated
SPIONs
To evaluate the eﬀect of incorporation of the SPIONs into
capsules, magnetization curves were acquired for capsules and
free particles; no diﬀerence was observed between the magnetic
properties of the free and encapsulated SPIONs (Fig. 1). Whilst
the properties of individual particles were not aﬀected by
encapsulation, the large number of particles in a single object
resulted in higher magnetic forces that enabled magnetic
separation of particles during purication from excessFig. 1 Characterization of free and encapsulated SPIONs by transmissio
ence device (SQUID). TEM of free and encapsulated SPIONs is presented i
Nanoscale Advancesreactants. Thus, during LbL assembly of particles in polymeric
capsules, as the number of particles per capsule increased, their
magnetic separation by a bar magnet became possible. Aer
deposition of 3 layers of SPIONs, for further layer deposition,
the excess reactants were therefore removed by magnetic
separation instead of centrifugation. The transmission electron
micrographs (Fig. 1a and b) show that particles did not fuse
inside the capsules; they retained their identity as individual
particles (as indicated by the magnetization curve; Fig. 1c). The
crystalline structure and particle size (8 nm) was conrmed by
powder XRD (pXRD) before encapsulation (Fig. SI.1a†). Their
hydrodynamic diameter in water was measured by dynamic
light scattering (DLS, 85 nm, Fig. SI.1b†). The hydrodynamic
diameter of capsules cannot be measured accurately by DLS
because of their dimension (mm size) and sedimentation
behavior.Eﬀect of encapsulation of particles on the solution relaxivity
To determine the eﬀect of encapsulation on the solution
relaxivity, the water relaxation rates of particles at diﬀerent
concentrations (based on Fe content) were measured by MRI
and plotted as function of concentration (Fig. 2). Encapsulation
of SPIONs resulted in a drop in solution relaxivity due to
hindered access to the solution water protons and is similar to
the previous ndings of the entrapment of free particles inside
the lysosomes.20,22,32 We used non-biodegradable polymers to
encapsulate the SPIONs to avoid the changes in solution
relaxivity and the resultant image contrast due to disassembly
of polymeric capsules.34Cell labelling eﬃciency and toxicity of SPIONs
mMSCs were chosen for this study because they are similar to
human bone marrow derived hMSCs which are being used in
clinical trials,41,42 and it has already been shown that these cells
uptake free SPIONs and other nanoparticle probes with good
eﬃcacy.12,22 To evaluate the cell labelling eﬃciency and toxicity
of free and encapsulated SPIONs, cells were labelled with
suspensions of particles (encapsulated or free) having compa-
rable Fe content. The cells were imaged by MRI to quantify then electron microscopy (TEM) and superconducting quantum interfer-
n (a) and (b), respectively. SQUIDmagnetisation curves are shown in (c).
This journal is © The Royal Society of Chemistry 2018
Fig. 2 Eﬀect of encapsulation of SPIONs on the solution relaxivity. The
water relaxation rates are plotted against the concentrations of
particles (in terms of Fe content).
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View Article Onlinesolution relaxation times (ms; Fig. 3a and b) and the Fe content
in labelled cells was determined with a ferrozine assay (Fig. 3c).
This revealed a two-fold higher Fe uptake by the cells whenFig. 3 Cell labelling and toxicity of SPIONs. The solution relaxation times
for cell labelling (a and b). The labelling concentrations of Fe (Fe added t
encapsulated SPIONs versus the added concentration of particles used fo
concentrations of 1.3, 1.75, and 2.2 mg mL1 corresponds to the doses of
concentrations of Fe is presented (d). The error bars are the standard de
This journal is © The Royal Society of Chemistry 2018labelled with encapsulated SPIONs as compared to the free
particles.
The diﬀerence in Fe uptake is unlikely to be due to electro-
static interactions,25,33 as both formulations were highly posi-
tively charged (Fig. SI.1c and d†). However, zeta potential
measurements for large sedimenting objects (encapsulated
SPIONs) is not reliable as sedimentation during the measure-
ment period aﬀects the accuracy of the data. Due to the large
number of SPIONs per capsule, the uptake of a few capsules per
cell resulted in increased Fe uptake per cell (Fig. 3c). Depending
upon the cell line/type and size/dimensions of capsules, the
number of micro capsules phagocytosed by cells cannot exceed
a limit of 2–15 capsules per cell.33 So for low labelling concen-
trations a higher Fe uptake is achieved by using encapsulated
particles. Higher degrees of labelling have been reported with
high labelling concentrations of free particles.19 In addition to
eﬃcient labelling at low Fe concentrations, capsules can be
used to combine nanoparticles in a single entity and hence can
facilitate multiplexed imaging and measurements.43
The toxic eﬀect of free and encapsulated particles is
comparable except at high doses of 125 and 250 capsules added
per cell (Fig. 3d). This may be due to the sedimentation of the
excessive encapsulated particles (mm dimension; all particles
cannot be endocytosed) resulting in the formation of a layer(T2 and T2*) of the particles are plotted against the concentrations used
o label the cells) are presented along abcisa. Internalization of free and
r cell labelling (determined from ferrozine assay) are shown (c). The Fe
15, 20, and 25 capsules added per cell. Cell viability against the labelling
viations of three replicates.
Nanoscale Advances
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View Article Onlineentirely covering the cells' surface leading to very high local
concentration. In the following sections, the cells were labelled
with particles below their toxicity level. For in vivo experiments,
15 capsules per cell (1.3 mg [Fe] mL1) and 2.6 times higher
concentration of free particles (3.3 mg [Fe] mL1) were added to
the cells to obtain a similar amount of iron per cell (4 and 5
pg Fe per cell, respectively).
Bioluminescence of mMSCs
To verify the mMSCs Luc+ bioluminescence signal, D-luciferin
was added to the cells and the bioluminescence signal was
detected aer 15 min of incubation using an IVIS spectrum
imaging system. It was noticed that the bioluminescence signal
from 200 cells was detectable (Fig. SI.2†), indicating that the
intensity of the bioluminescence signal was suﬃcient for in vivo
detection.
Cell phenotype aer labelling and re-seeding/re-spreading
To observe cell phenotype, the trypsinized cells suspended in
ice cold PBS for 5–6 h were plated (re-seeded). Three days post-
seeding the morphology of the labelled cells observed by light
microscopy was not distinguishable from unlabeled cells, irre-
spective of whether they were labelled with free or encapsulated
SPIONs (Fig. SI.3†), although more sophisticated morphology
analysis aer staining could reveal more subtle changes.44 The
capsules are visible inside the labelled cells by light microscopy
(Fig. SI.3†). It is well established that aer internalization,
capsules are localised inside the phago/lysosomes.33,34,45,46
Homing potential of the mMSCs may be aﬀected by incubation
with the particles which can be best checked by staining cell
specic markers.47
Animal injection and in vivo monitoring of the bio-
distribution of labelled cells
When cells are injected into mice, a signicant proportion of
them die within a short time-frame.5,42,48 Due to the impact on
the interpretation of imaging results and particles' associated
toxicity, it is important to determine the fate of particles once
labelled cells die. Hence, soon aer injecting the labelled
mMSCs into mice, their in vivo bio-distribution was monitored
in parallel by BLI and MRI for 14 days. As expected, the vast
majority of the cells were no longer detectable by day 1. The cells
transduced with lentiviral vector (Luc+) upon interaction with D-
luciferin (injected intraperitoneally in mice) within 15 min
convert D-luciferin to optically active oxyluciferin. The BLI signal
of optically active oxyluciferin can be used as indicator of cells
viability.12 The disappearance of in vivo BLI signal upon injec-
tion of D-luciferin conrmed that the majority of the injected
cells were dead. Surprisingly, in some animals, a strong lumi-
nescence signal was detected in the cardiac regions throughout
the course of imaging (Fig. 4); this was likely due to small
numbers of cells from the needle tract engraing in the cardiac
muscles following IC administration. By day 14, luminescence
signals were present in the hind regions of some mice. As we
have previously shown, these were likely to be osteosarcomas
resulting from the proliferation of the transplanted cells.11 OnNanoscale Advancesculling the mice, no tumor was detected in the major body
organs (liver, spleen, brain, heart, and lungs). A key objective of
this study was to investigate what happened to the free and
encapsulated SPIONs aer day 1 when BLI showed that the
majority of the cells had died. For this purpose, we require
consecutive MRI and BLI to be performed on the same animals.MRI complementary to BLI
The high resolution of MRI facilitates the visualization of the
intra-organ bio-distribution of the contrast agent.11 Here, MRI
allowed the monitoring of in vivo clearing and accumulation
pattern of particles (Fig. 5 and SI.4†), aer conrmation of cell
death by BLI. Since the major Fe accumulation and clearing/
elimination organs are kidneys, liver, and spleen, we imaged
the entire abdominal region of mice by MRI throughout the
course of experiments to assess the presence and distribution of
the particles. Signicant diﬀerence in contrast can be seen in the
images over the time-course of the experiment, being highest
soon aer injection and reducing towards baseline over the
following days (Fig. SI.4†). Full MRI datasets are available on the
Zenodo data archive; https://doi.org/10.5281/zenodo.1203991.
To quantify the Fe accumulation and clearance pattern
before and aer injection, the T2* relaxation times (ms) in some
organs and tissues (liver, spleen, spinal muscles, kidney cortices
and medullae) were calculated (Fig. 5) from the MRI scans by
drawing regions of interests (ROIs) around these organs and
tissues. The most important parameter to track particles by MRI
is the generation of negative contrast due to the presence of
SPIONs. The decrease in the T2* relaxation times (caused by the
dephasing or inhomogeneity from the presence of super-
paramagnetic iron oxide particles) distorts the local magnetic
eld, thereby reducing the signal, which appears as dark spots
or signal void in MR images.20 Hence the presence of more
SPIONs (free or encapsulated) resulted in a decrease in the
relaxation times generating negative contrast. We have corre-
lated the drop in the relaxation time with the amount of SPIONs
present/accumulated inside some organs in vivo. The reversion
back of relaxation times close to the baseline values (before
injection of labelled cells) gave an indication of clearance of
SPIONs from these organs. Soon aer injection, the relaxation
time decreased in the liver for both free and encapsulated
SPIONs and a further decrease can be seen in the following days
post-injections. The BLI data indicates that 24 hours post-
injection there was considerable cell death. Therefore, the
decrease in relaxation time in the liver on day 1 and 2 post-
injection is possibly due to SPIONs accumulating in the liver
following their release from cells. The presence of SPIONs in the
liver up to 48 hours post administration is in accordance to the
recent ndings of Scarfe et al.11 On day 6 post-injection, the
relaxation time in the liver started to increase but remained
below the baseline value during the entire time course of
imaging (Fig. 5). This suggests that the SPIONs accumulated in
liver were not completely cleared/eliminated by day 14. The
tendency of accumulation and hence slow clearance of SPIONs
from the liver of mice aer cell death is similar to the fate of free
particles systemically injected in mice.36This journal is © The Royal Society of Chemistry 2018
Fig. 4 In vivo long term fate of labelled mMSCs determined from bioluminescence imaging. Images taken at diﬀerent days post injection of
labelled cells. Left panels in each image set (each day) represent mice injected with mMSCs labelled with free SPIONs. While, right panels
represent mice injected with mMSCs labelled with encapsulated SPIONs. Upper and lower rows show dorsal and ventral aspects, respectively.
Images were recorded 15 minutes after intraperitoneal (IP) injection of D-luciferin.
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View Article OnlineThe spleen has very short relaxation time values at the
baseline imaging time point, and no further reduction was
observed until the last imaging day in the case of free SPIONs
(Fig. 5). By contrast, relaxation times appeared to be lower for
encapsulated SPIONs at day 14 post injection. Interestingly, theFig. 5 Relaxation times (T2*) as function of time. T2* relaxation times o
Diﬀerent symbol shapes represent diﬀerent animals.
This journal is © The Royal Society of Chemistry 2018relaxation times for encapsulated SPIONs had increased in the
liver at this time point, suggesting that aer leaving the liver,
encapsulated particles accumulated inside the spleen. However,
detailed biochemical pathways for Fe accumulation in these
organs needs to be explored. Recently, the long term in vivo fatef SPIONs in diﬀerent organs and tissues are plotted at diﬀerent days.
Nanoscale Advances
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View Article Onlineof diﬀerent hybrids of SPIONs with gold nanoparticles has been
established aer directly injecting the particles in the blood
stream of mice which revealed a predominant accumulation of
particles in liver and spleen for longer periods of time.36 In
similar studies, the accumulation and metabolism of particles
in the liver and spleen and loss of magnetic characteristics as
a function of their surface coating, inner core and formation of
protein corona was evaluated.37–40 The electron paramagnetic
resonance (EPR) based measurements of iron oxide nanocubes
showed their considerable elimination from liver on day 7 post
administration, whereas half of the proportion of particles
stored in the spleen was still detected on day 7 post injec-
tion.39,40 In general, free SPIONs have faster lysosomal degra-
dation and cellular elimination rate as compared to the
aggregated particles.49 Here it is important to mention that the
SPIONs can be degraded inside the cells before their in vivo
release upon cell death.50 We speculate that the polymer coating
by non-biodegradable materials might reduce the intra-cellular
degradation of SPIONs in a similar way that gold coating has
been shown to successfully protect the iron oxide core from
intra-cellular degradation.51
The relaxation time and MRI contrast in spinal muscles did
not change considerably throughout the time course of experi-
ments (Fig. 5 and SI.4†). The SPIONs detected in the kidney
cortices and medullae immediately aer administration were
mostly cleared by day 1 post injection (Fig. 5). This nding
suggests that aer cell death, the particles were rapidly cleared
from the kidneys, in line with what has been reported for the
intravenous and IC injected particles where particle accumula-
tion inside kidneys is not observed.11Inductively coupled plasma-optical emission spectrometry
(ICP-OES) based Fe quantication
To conrm the results of the MRI analysis, at the end point of
imaging experiments the animals were culled and ex vivo ICP-
OES based Fe quantications in 6 organs (brain, kidney, liver,
lung, spleen & heart) were performed (Fig. SI.5†). This analysis
did not show a signicant diﬀerence in the percentage of Fe per
dry weight of organs at day 14 post injection from the control
group of mice which did not receive any injection. This suggests
that the majority of the particles released on cell death were
cleared by 2 weeks. Although the sensitivity of such measure-
ments is limited as the presence of high quantities of endoge-
nous Fe and animal-to-animal variability renders their
interpretation diﬃcult. More elaboratemeasurement strategies,
e.g. isotope labelling,37,52,53 could be employed in future studies.Materials and methods
Materials and reagents
Diethylaminoethyl (DEAE)-dextran (Mw 40 kDa, #80881), iron(III)
chloride hexahydrate (#1.03943), iron(II) chloride tetrahydrate
(98%, #380024), ammonium hydroxide solution (28–30%,
#221228), sodium azide (#S2002), calcium chloride dihydrate
(#223506), sodium carbonate (#S7795), sodium chloride
(#S7653), poly(sodium 4-styrenesulfonate) (PSS, Mw  70 kDa,Nanoscale Advances#243051), dextran (average Mw 1500–2800 kDa, #D5376), ethyl-
enediaminetetraacetic acid disodium salt dihydrate (EDTA,
#E5134), sterile dimethyl sulfoxide (DMSO, #D2650),
Sephadex® G-100 beads (#GE17-0060-01), 3-(2-pyridyl)-5,6-di(2-
furyl)-1,2,4-triazine-50,500-disulfonic acid disodium salt (ferro-
zine reagent, #82940), 2-hydroxyethyl agarose (low gelling
temperature, #A4018 and #A9414), sucrose (#S7903), L-ascorbic
acid (#95209), ammonium acetate (#A1542), neocuproine
(#N1501), and Corning®spin-lters (100 kDa, #CLS431491),
were purchased from Sigma Aldrich. Spectra/pore biotech
cellulose ester (CE) dialysis membranes (MWCO: 100 kDa,
#11415949) and Millex GP syringe lters with polyethersulfone
(PES) membranes (0.22 mm, #10038041) were purchased from
Fisher Scientic, UK. Membrane lters (#SLHAO33SS; pore size
0.45 mm, and #780532; 0.22 mm) were from Millex HA Millipore
and STARLAB, respectively. Poly(allylamine hydrochloride)
(PAH,Mw 120–200 kDa, #43092.09) was purchased from VWR.
Gelatin capsules (size 4, #AGG29214) were from Agar Scientic.
Double distilled deionized (Millipore Limited, Hertfordshire,
UK) water with resistivity of 18.2 MU cm was used in all
experiments.
Luciferase transduced bone marrow derived mouse mesen-
chymal stem cell line (mMSCs; D1 ORL UVA [D1]ATCC®, #CRL-
12424™) was generously provided by Dr Antonius Plagge and
was a gi from Bryan Welm (Addgene plasmids #21375 and
39196). For cell culture, Dulbecco's modied Eagle's medium
(DMEM, #D6546), phosphate buﬀered saline (PBS; #806544),
PBS tablets (#P4417), and penicillin–streptomycin (P/S, #P4333)
were purchased from Sigma-Aldrich. L-Glutamine (#25030081),
fetal bovine serum (FBS; #16000044), and 0.5% trypsin–EDTA
(#15400054) were purchased from GIBCO (Life Technologies).
Paraformaldehyde (PFA, 16%, #28908) was from Thermo Fisher
Scientic. Cells were counted by an automated cell counter
(TC20™) from Bio Rad. CellTiter-Glo® reagent (#G7570) was
from Promega. Cell culture Petri dishes (PS, 100/20 mm, vents,
Cellstar® #664970), and falcon tubes (Cellstar®; 15 mL;
#188271, and 50 mL; #227261) were from Greiner Bio-one. 24
well plates (#3524) were from Costar (Corning). 100 well trans-
parent (#167008) and opaque bottom plates (#CLS3917) were
from Thermo Scientic and Sigma Aldrich, respectively.
Eppendorfs (1.5 mL; #0030120086) were from Eppendorf. 100
(#981103) and 200 mL (#I1402-8100) polypropylene tubes
(Eppendorfs) were purchased from Qiagen and STARLAB,
respectively. Centrifuge machines (Sigma 2-6E) and (Heraeus
Pico 21, Thermoelectron Corporation) were used for centri-
fuging the mMSCs. Formvar/carbon-coated 200 mesh copper
grids (#F077/100) were purchased from TAAB.Characterization tools
The hydrodynamic diameter and zeta potential measurements
were performed in water using a Malvern zetasizer Nano ZS
(dynamic light scattering). According to the manufacturer's
instructions, the ATP assay (Cell Titer-Glo luminescent assay,
Promega) based luminescence (for determination of viability of
cells) and ferrozine reagent assay based colorimetric changes
(for quantication of iron content) were measured with FluostarThis journal is © The Royal Society of Chemistry 2018
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View Article OnlineOmega (BMG Labtech) coupled with a microplate reader.
Transmission electron microscope (TEM) micrographs were
taken using a Tecnai G3 spirit TEM at 120 keV. 5 mL droplets of
the diluted samples were drop-casted onto the formvar/carbon-
coated 200 mesh copper grids and air dried before TEM anal-
ysis. The morphology of mMSCs was observed by bright eld
(Leica light microscope DM IL coupled with Leica DFC 420C
camera) microscopy. For ICP-OES Agilent 5110 ICP-OES spec-
trometer (with SVDV detection and equipped with the sample
changer) was used. To determine the crystalline state and mean
core diameter of free SPIONs powder X-ray diﬀraction (pXRD)
measurements were carried out on a Panalytical X'pert Pro
multipurpose diﬀractometer (Co Ka source, l¼ 1.78 A˚, patterns
measurement >20–120 2q for 2 hours, step size ¼ 0.033, time/
step ¼ 295.3 s, scan speed ¼ 0.014 s1). Particles samples were
freeze-dried using Labconco freezone 4.5 (condenser tempera-
ture 50 C, shelf temperature 20 C) and their magnetization
behaviour (magnetic isotherm) was recorded by means of
a superconducting quantum interference device (SQUID)
magnetometer (MPMS XL-7, quantum design, USA) at 300 K
with maximum applied eld 2 T under helium atmosphere. For
SQUID measurements, freeze-dried samples (a few mg) were
embedded in gelatin capsules (size 4) which were suspended in
the middle of plastic drinking straws. Organs were freeze-dried
to obtain their dry weight before ICP-OES based quantication
of iron. For bioluminescence (BLI) measurements a biolumi-
nescence imager (IVIS Spectrum, Perkin Elmer, UK) was used to
see the in vivo biodistribution of mMSCs. Magnetic resonance
imaging (MRI) was performed with Bruker Avance III spec-
trometer interfaced to a 9.4 T magnet system (Bruker Biospec
90/20 USR) using a 40 mm transmit/receive volume coil for
SPIONs phantoms, SPIONs-labelled cell phantoms and animal
imaging. Ultrasound system (Prospect) with ultrasound pulse
sequence (UPS) user interface from S-Sharp Corporation Taiwan
was used during IC injections of labeled mMSCs to mice.
Animals
6–8 week old 11 female BALB/c mice were obtained from
Charles River, UK and housed in groups of 4 with ad libitum
access to standard food and water (ventilated cages, 12 h light/
dark cycle). Animal experiments were approved by the Univer-
sity of Liverpool (UoL) ethics committee and performed under
a licence granted by the UK Home Oﬃce under the Animals
(Scientic Procedures) Act 1986. Reporting of experiments is in
line with the ARRIVE guidelines. Animals were closely observed
for any side eﬀects and were culled at the end of experiments
(day 14 post injection) without observing a noticeable tumor
mass.
Methodology
Synthesis of super-paramagnetic iron oxide (maghemite)
nanoparticles (SPIONs). SPIONs were synthesized following the
published protocol from Barrow et al.19,20 Briey, maghemite
(SPIONs) were synthesized by mixing DEAE-dextran (0.05 g, Mw
40 kDa), ferric chloride hexahydrate (0.03 g), and ferrous chlo-
ride tetrahydrate (0.015 g) in 25 mL water with non-magneticThis journal is © The Royal Society of Chemistry 2018(polytetrauoroethylene) stirring under an air-tight connec-
tion. The mixture was purged with nitrogen on ice (30 minutes)
and ammonium hydroxide (1 mL, 28–30%) was added dropwise
(in 2 min) under stirring (200  5 rpm). This was followed by
mixture transfer from ice to an oil bath (pre-set at 60 C) and
temperature elevation to 80 C under nitrogen (in 15 min) and
then le at 80 C for 1 h. Aerwards, the product was brought
under air, and reuxed for 5 h at 110 C. SPIONs were puried at
room temperature by dialysis (100 kDa membrane) until the pH
became neutral (7). Aer concentrating by spin lter (1–2 mL),
the sample was passed through size exclusion beads (dextran-
based G-100 Sephadex®) to remove excess free polymer.
Finally, the particles were washed thrice with deionized water by
spin lteration. SPIONs were passed through 0.22 mm poly-
ethersulfone (PES) membrane for sterilisation before use in
experiments and saved at 4 C.
Synthesis of SPIONs encapsulating PEM capsules. SPIONs
were encapsulated by a modied co-precipitation method,28,34
and LbL assembly of oppositely charged layers of polymers and
SPIONs around co-precipitated cores. PEM capsules consisting
of 32 layers [(PSS/PAH/PSS/SPIONs)7/(PSS/PAH)2] of non-
biodegradable polymers, i.e., PSS and PAH, and SPIONs were
fabricated around sacricial template cores comprising of
calcium carbonate incorporating SPIONs and high molecular
weight dextran. In order to co-precipitate SPIONs and dextran
with calcium carbonate microparticles, solutions of calcium
chloride and sodium carbonate were mixed under vigorous
stirring in the presence of SPIONs and dextran at room
temperature. For this in a glass vial, 4.2 mL mixture (0.3 mL
SPIONs; 0.95 mg mL1, 1 mL dextran; 6.5 mg mL1, and 2.9 mL
water) was added to 3 mL of calcium chloride solution (0.33 M).
3 mL of sodium carbonate solution (0.33 M) was quickly added
to the above mixture and continuously stirred for 30 s, under
vigorous magnetic stirring (1500 rpm) followed by keeping the
reaction contents without agitation for 2 min at room temper-
ature. The resulting calcium carbonate particles incorporating
SPIONs and dextran were washed thrice with deionized water
and used for LbL assembly of oppositely charged poly-
electrolytes (2 mg mL1 in 0.5 M NaCl) and SPIONs (0.5 mL
SPIONs; 0.95 mg mL1, 4 mL water, and 0.5 mL; 0.5 M sodium
chloride). The alternating layers of negatively and positively
charged polymers, and SPIONs were electrostatically deposited
around the charged sacricial microparticle template cores
following an established protocol.54,55 For this the microparti-
cles were alternatively immersed inside the solutions of either
layer (5 mL; PSS, PAH, or SPIONs), exposed to sonication for
short time (1–3 min) and kept under agitation/shaking for
13 min. Aer deposition of each layer the particles were washed
thrice with deionized water to remove excess reactants
(polymers/SPIONs, etc.). Finally, the cores of PEM capsules were
dissolved by complexion of calcium ions with EDTA (5 mL,
0.2 M, pH 6.5; 30 min incubation), washed with deionized
water, and stored at 4 C aer addition of 10.5 mL water for
further use. The capsules diameter was2 mm as observed from
TEM analysis. Further in the manuscript these PEM capsules
incorporating SPIONs are called encapsulated SPIONs.Nanoscale Advances
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View Article OnlineFor SQUID measurements, free and encapsulated SPIONs
were freeze-dried and SQUID measurements, TEM, pXRD (free
SPIONs), zeta size and potential measurements were performed
as mentioned in the characterization section.
Ferrozine assay and ICP-OES based Fe quantication. The
samples (particles and particle-labelled cells) were dissolved in
1.2 M HCl. Fe standard curves were made from the known
concentrations of Fe and from these standard curves the
unknown concentrations of Fe in the samples were determined.
For ferrozine assay, the Fe standard (50 mL, 4 mg in 1.2 M
HCl) was serially diluted in HCl (1.2 M) followed by addition of
50 mL water so that nal Fe concentration in standards was 2, 1,
0.5, 0.25, 0.125, 0.0625, 0.031 mg in HCl (0.6 M; 100 mL). Blank
was 100 mL HCl (0.6 M). In the samples with unknown Fe
content, 50 mL HCl (1.2 M) was added and samples, Fe stan-
dards and blank were placed on a heat block at 65 C for 2 h.
Aer heat-assisted acid dissolution, the samples and standards
were cooled down to room temperature and centrifuged to
collect the condensation products along the walls of tubes. HCl
concentration was adjusted to 0.6 M by adding water. 30 mL
ferrozine reagent was added to 100 mL of each sample including
standards and blank, mixed and le at room temperature for
30 min. Their absorption was measured at 590 and 780 nm
using a plate reader. For background correction the absorbance
at 780 nm was subtracted from the absorbance at 590 nm and
blank was subtracted from all values. A standard curve for Fe
content was plotted and was used to quantify Fe contents in the
samples with unknown Fe concentrations.
(Note: the ferrozine reagent was prepared by dissolving 2.4 g
ammonium acetate, 2.2 g ascorbic acid, 0.02 g ferrozine, and
0.02 g neocuproine (dissolved in small volume of ethanol) in
6.25 mL water, mixed, frozen in small aliquots and protected
from light).
For ICP-OES Fe quantications aer dissolution with 1.2 M
HCl, the samples were diluted in water so that nal acid content
will not exceed 5%. ICP-OES measurements were performed
using 3 readings per wavelength and 11 wavelengths per
sample. The concentration determination was performed using
calibration curve for Fe consisting of 6 measurement points of
freshly prepared Fe concentrations (0–10 mg mL1) derived from
iron standard solutions from Inorganic Ventures (100 mg L1).
Cell viability measurements. CellTiter-Glo® reagent was
used for cell viability measurements. For this assay, mMSCs
were seeded in 96 well transparent bottomed plates at 10 000
cells per well in 100 mL complete cell growth medium (DMEM
supplemented with 10% FBS, 1% P/S, and 1% L-glutamine).
Aer 24 h cells were incubated with free and encapsulated
SPIONs suspended in fresh cell culture medium for 24 h. Serial
dilution of particles was performed in complete cell growth
medium. Each condition was applied in triplicate. Aer incu-
bation with particles, the cells were washed with PBS and 100 mL
fresh cell growth medium was added to each well of assay
plates, followed by the addition of 20 mL CellTiter-Glo® reagent.
The plates were shaken at 600–700 rpm in an orbital shaker for
1 min (to complete cell lysis), incubated at room temperature
for 5 min and 100 mL mixture contents from each well of the
plates were transfered in opaque bottomed 96 well plates. TheNanoscale Advancesluminescence from each well of 96 well plate was measured by
a Fluostar Omega (BMG Labtech) plate reader. Viability was
expressed as % of the untreated control.
Phantoms for MR measurements. Phantoms for MR
measurements were prepared in 1% low melting agarose.
1 Phantoms of particles. Low melting agarose was dissolved
in water at 65 C to get a clear 2% solution and placed at 40 C
during mixing and addition of particles. The solutions of
SPIONs (free and encapsulated) were diluted in water (serial
dilution) to get 0.5, 0.25, 0.125, 0.0625, and 0.03125 mM Fe
concentrations. These diluted solutions of particles were mixed
with the gel at 40 C (1 : 1 dilution by volume; 100 mL of each
sample was mixed throughly with 100 mL gel without bubble
formation in 200 mL polypropylene tubes) to get nal Fe content
0.25, 0.125, 0.0625, 0.03125, and 0.0156 mM in 1% agarose. 2%
agarose was mixed with water (1 : 1 dilution) to serve as control.
These samples were mounted in 1% agarose containing
holders, stored at 4 C for 24 h and analyzed by MRI. The MR
measurement parameters are listed in Table SI.1.† The solution
relaxivity of the particles entrapped in phantoms was calculated
from their relaxation times which were acquired by multi
gradient echo sequences (MGES) and the imaging was per-
formed with a fast low angle shot (FLASH) sequence.
2 Phantoms of labelled cells. In 6 well plates mMSCs were
seeded (2  105 cells per well) in 2 mL complete growth media.
Aer 24 h the free and encapsulated SPIONs were added at 15,
20, and 25 capsules per cell (equivalent to a dose of 13.1, 17.5,
and 21.8 pg Fe in free SPIONs per cell) considering the seeded
number of cells. Aer 24 h of incubation, cells were washed
twice with PBS and trypsinized. Particle-labelled cells were
centrifuged at 500 rcf for 5 min and the supernatant was
removed. The cell pellets were resuspended in 4% PFA, mixed
without bubble formation and xed cells were transfered in
small polypropylene tubes (100 mL for each condition) centri-
fuged and maximum supernatant was removed. The cell pellets
were resuspended in PBS and mixed with 2% low melting
agarose (1 : 1 dilution). 3  105 xed cells were poured on the
top of already solidied 1% agarose gel. The samples were
mounted in 1% agarose containing holders and imaged with
a fast low angle shot (FLASH) sequence. 19 images per sample
were captured. Their T2 and T2* relaxation times were
measured with MGES. Imaging parameters are listed in Table
SI.2.†
For ferrozine based Fe quantication, the particles labelled
cells (aer washing and trypsinization) were counted, centri-
fuged and dissolved in HCl (1.2 M) aer removing maximum
supernatant.
Luc+ activity of mMSCs. The cells were monitored for Luc+
activity before in vivo experiments. For this mMSCs were seeded
in 96 well plates in triplicate with serial dilutions (10 000, 5000,
2500, 1250, 625, 312, 156, 78, 39, 20, 7, 3, 2, 1, and 0 cells per
well) in 100 mL complete growth media and cultured at constant
(5%) supply of CO2 for 24 h at 37 C. Aer refreshing the growth
media, the plates were placed in IVIS spectrum imaging system,
and noted the baseline bio-luminescence signals. Latter, their
growth media was replaced by fresh growth media (100 mL)
containing D-luciferin (15 mg mL1), le at room temperatureThis journal is © The Royal Society of Chemistry 2018
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View Article Onlinefor 15 min and their bio-luminescence was recorded and
expressed as radiance (photons per second per cm2 per stera-
dian [p s1 cm2 sr1]).
Cell labelling and administration in mice. mMSCs trans-
duced with lentiviral vector (Luc+) were IC injected in mice. The
vector details are described in a recent study.12 To label cells
with particles, 1.5  106 mMSCs were seeded in 100 mm tissue
culture dishes and incubated for 24 h at 37 C in humidied
atmosphere with 5% CO2. Free (33.72 pg Fe per cell) and
encapsulated (@15 capsules per cell equivalent to a dose of 13.1
pg Fe per cell) SPIONs were added to the cells considering the
seeded number of cells and incubated for 24 h. The cells were
washed twice with PBS, trypsinized, kept on ice (aer removing
trypsin), and resuspended in ice cold PBS aer cell counting. To
observe the morphology of cells aer particles labelling, some
of the trypsinized cells were re-seeded and imaged aer 3 days.
106 cells in 100 mL PBS (having 5 and 4 pg Fe per cell for free
and encapsulated SPIONs, respectively) were IC injected into
the le ventricles of female BALB/c mice under ultrasound
guided injection. Details of IC injections is provided in a recent
study.11 Briey, mice were anesthetized with a mixture of iso-
urane and oxygen, subcutaneous (SC) injected with an anal-
gesic buprenorphine (0.1 mg kg1 body weight) and were
positioned supine above a heated platform. Their fur was
removed and the limbs and abdomen were taped aer exten-
sion of body (to hold body in extended position and the skin
over the chest taut). Ultrasound gel was applied to the chest,
and ultrasound transducer was positioned over the mice to have
chest in view. Visualized the heart and labelled cells were
injected inside the le cardiac ventricle with the help of 29G 1/2
inch insulin syringe. The cells were completely re-suspended,
and were injected in a slow and well controlled manner. Soon
aer IC injections mice were imaged by MR under the same
anaesthesia session and latter in groups of 4 by IVIS based BLI,
on 0 (injections day), 1, 2, 6, 10, and 14 days post injections.
Where possible mice were imaged by both imaging modalities
under same anesthetic session. The mice were recovered from
anaesthesia in a heat box set at 32 C, and closely monitored for
the signs of any adverse eﬀects during the course of studies.
In vivo MR imaging. The biodistribution of cells in the
abdominal region, i.e., kidneys, liver, spinal muscles, and
spleen was imaged with a 9.4 T horizontal bore MRI scanner
(Bruker Avance III spectrometer) using a 40 mm transmit/
receive volume coil. FLASH T2* weighted sequences were
recorded and T2* maps were generated using MGES. A prescan
before injections served as control to set baseline value for MR
analysis. Regions of interests (ROIs) were drawn around the
kidney cortices, medullae, liver, spleen and spinal muscles and
T2* relaxation times were calculated from the T2* maps. MR
acquisition parameters are listed in Table SI.3.†
Bioluminescence imaging (BLI). BLI complementary to each
MR scan was performed until the last imaging day (day 14 post
injection). Mice received D-luciferin (150 mg kg1 body weight)
intraperitoneally and were imaged 15 min post injections by
IVIS spectrum imaging system. Imaging was performed by 1–
3 min luminescence exposure and expressed as radiance
(photons per second per cm2 per steradian [p s1 cm2 sr1]).This journal is © The Royal Society of Chemistry 2018ICP-OES based Fe quantication in mice organs. For quan-
tication of Fe content in the brain, kidneys, liver, lungs,
spleen, and heart, at the end of in vivo experiments mice were
euthanized under terminal anesthesia followed by cervical
dislocation. Aer dissection, the above mentioned organs were
collected, washed with PBS and preserved in 70% ethanol.
Organs collected from 3 untreated mice served as control. The
organs in 70% ethanol were dipped in 96% ethanol, crushed
with pestle and mortar and le overnight for freeze-drying. The
dried crushed organs mass was weighed. 0.5 mL HCl (1.2 M)
was added to the dried and crushed organs, kept inside an oven
at 70 C for 3 h and brought the reaction contents at room
temperature. Water was added to each sample vial to get 10 mL
nal volume. Samples were ltered through 0.2 mm lters to
remove organ debris. Fe content in each sample was deter-
mined by ICP-OES. The dried weight of crushed organs noted
before acid digestion was used for normalizing Fe content per
dried weight of each organ.
Conclusions
We have demonstrated that SPIONs can be encapsulated inside
polymeric capsules while retaining their individual particle
identities and demonstrated similar magnetization behavior as
free particles. Although the solution relaxivity of free particles
was very diﬀerent from encapsulated ones, once internalized
inside lysosomal compartments aer cell uptake, this diﬀer-
ence became negligible for similar concentrations (Fe) of
particles. The encapsulation of particles has some potential
advantages over free particles; e.g., (1) in case of cell labelling
with small amount of particles, a higher uptake can be ach-
ieved, and (2) the addition of diﬀerent types of particles in
a single entity for multiplexed measurements is possible.
Comparison of both formulations of SPIONs did not reveal any
diﬀerence in the in vivo fate of particles upon cell death and was
similar to what has been reported for particles directly injected
in the blood stream of mice.
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